Gene profiling predicts rheumatoid arthritis responsiveness to IL-1Ra (anakinra)

Rheumatology

Volumn 50, Issue 2, 2011, Pages 283-292

  Bansard, Carine ^a   Lequerré, Thierry ^a,b,c   Derambure, Céline ^a,c   Vittecoq, Olivier ^a,b,c   Hiron, Martine ^a   Daragon, Alain ^a,b   Pouplin, Sophie ^b   Daveau, Maryvonne ^a,c   Boyer, Olivier ^a   Tron, François ^a,c   Le Loët, Xavier ^a,b,c   Salier, Jean Philippe ^a,c  

^a UNIVERSITÉ DE ROUEN   (France)

^b ROUEN UNIVERSITY HOSPITAL   (France)

^c Consortium EGERIE ^*  (France)

Author keywords

Biologics; Biomarkers; Personalized medicine; Pharmacogenomics; Predictive markers; Rheumatoid arthritis

Indexed keywords

INTERLEUKIN 1BETA; MESSENGER RNA; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ADD ON THERAPY; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CORTICOSTEROID THERAPY; FEMALE; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; MALE; MICROARRAY ANALYSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RELIABILITY; REPRODUCIBILITY; RHEUMATOID ARTHRITIS; RNA ANALYSIS; SCORING SYSTEM; TREATMENT RESPONSE;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; FEMALE; GENE EXPRESSION PROFILING; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; METHOTREXATE; MIDDLE AGED; TREATMENT OUTCOME; VALIDATION STUDIES AS TOPIC;

EID: 78751699507     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq344     Document Type: Article

References (41)

1. Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med 2004;50:2167-79.
2. O'Dell JR. Anticytokine therapy-a new era in the treatment of rheumatoid arthritis? N Engl J Med 1999;340:310-2.
3. Furst DE, Breedveld FC, Kalden JR et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis 2007;66:iii2-22.
4. Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. Lancet 2007;370:1861-74.
5. Furst De, Breedveld FC, Kalden JR et al. Updated consensus statement on biological agents, specifically tumour necrosis factor alpha blocking agents and interleukin-1 receptor antagonist, for the treatment of rheumatic diseases, 2005. Ann Rheum Dis 2005; 64(Suppl. 4):iv2-14.
6. Pavy S, Toonen EJ, Miceli-Richard C et al. Tumour necrosis factor alpha -308G->A polymorphism is not associated with response to TNFalpha blockers in Caucasian patients with rheumatoid arthritis: systematic review and meta-analysis. Ann Rheum Dis 2010;69: 1022-8.
7. Stuhlmüller B, Häupl T, Hernandez MM et al. CD11c as a transcriptional biomarker to predict response to anti-TNF monotherapy with adalimumab in patients with rheumatoid arthritis. Clin Pharmacol Ther 2010;87:311-21.
8. Lequerré T, Jouen F, Brazier M et al. Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab. Rheumatology 2007;46:446-53.
9. Lequerré T, Gauthier-Jauneau AC, Bansard C et al. Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis. Arthritis Res Ther 2006;8:R105-15.
10. Jiang Y, Genant HK, Watt I et al. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum 2000;43:1001-9.
11. Cohen S, Hurd E, Cush J et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:614-24.
12. Nuki G, Bresnihan B, Bear MB, McCabe D. European Group of Clinical Investigators. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:2838-46.
13. Fleischmann RM, Schechtman J, Bennett R et al. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial. Arthritis Rheum 2003;48:927-34.
14. Schiff MH, DiVittorio G, Tesser J et al. The safety of anakinra in high-risk patients with active rheumatoid arthritis: six-month observations of patients with comorbid conditions. Arthritis Rheum 2004;50:1752-60.
15. Le Loët X, Nordström D, Rodriguez M et al. Effect of anakinra on functional status in patients with active rheumatoid arthritis receiving concomitant therapy with traditional disease modifying antirheumatic drugs: evidence from the OMEGA trial. J Rheumatol 2008;35: 1538-44.
16. Burger D, Dayer JM, Palmer G, Gabay C. Is IL-1 a good therapeutic target in the treatment of arthritis? Best Pract Res Clin Rheumatol 2006;20:879-96.
17. den Broeder AA, de Jong E, Franssen MJ, Jeurissen ME, Flendrie M, van den Hoogen FH. Observational study on efficacy, safety, and drug survival of anakinra in rheumatoid arthritis patients in clinical practice. Ann Rheum Dis 2006;65:760-2.
18. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315-24.
19. van Gestel AM, Prevoo ML, van't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League against Rheumatism criteria. Arthritis Rheum 1996;39: 34-40.
20. Guillemin F, Braincon S, Pourel J. Measurement of the functional capacity in rheumatoid polyarthritis: a French adaptation of the Health Assessment Questionnaire (HAQ). Rev Rhum Mal Ostéoartic 1991;58: 459-65.
21. Coulouarn C, Lefebvre G, Derambure C et al. Altered gene expression in acute systemic inflammation detected by complete coverage of the human liver transcriptome. Hepatology 2004;39:353-64.
22. Rozen S, Skaletsky HJ. Primer3 on the WWW for general users and for biologist programmers. In: Krawetz S, Misener S, eds. Bioinformatics methods and protocols: methods in molecular biology. Totowa, NJ: Humana Press, 2000:365-86.
23. Tahi F, Achddou B, Decraene C et al. Automatic quantitation of hybridization signals on cDNA arrays. BioTechniques 2002;32:1386-97.
24. Fundel K, Haag J, Gebhard PM, Zimmer R, Aigner T. Normalization strategies for mRNA expression data in cartilage research. Osteoarthr Cartil 2008;16:947-55.
25. Graphpad Instat. http://www.graphpad.com (15 April 2010, date last accessed).
26. Tmev version 2.2. http://www.tm4.org (15 April 2010, date last accessed).
27. Genomatix. http://www.genomatix.de (15 April 2010, date last accessed).
28. Gene Expression Omnibus. http://www.ncbi.nlm.nih.gov/projects/geo (15 April 2010, date last accessed).
29. Scheinecker C, Redlich K, Smolen JS. Cytokines as therapeutic targets: advances and limitations. Immunity 2008;28:440-4.
30. Jarvis JN, Centola M. Gene-expression profiling: time for clinical application? Lancet 2005;365:199-200.
31. Olsen NJ, Moore JH, Aune TM. Gene expression signatures for autoimmune disease in peripheral blood mononuclear cells. Arthritis Res Ther 2004;6:120-8.
32. Toonen EJ, Barrera P, Radstake TR et al. Gene expression profiling in rheumatoid arthritis: current concepts and future directions. Ann Rheum Dis 2008;67:1663-9.
33. Cai Y, Kitajima S, Etoh F, Kinoshita S, Okubo K, Hamasaki N. Autoantibody reactive with the human general transcription factor TFIIF in sera from patients with autoimmune disorders. Clin Exp Immunol 1997;109: 488-94.
34. Goëb V, Thomas-L'Otellier M, Daveau R et al. Candidate autoantigens identified by mass spectrometry in early rheumatoid arthritis are chaperones and citrullinated glycolytic enzymes. Arthritis Res Ther 2009;11:R38-51.
35. Busso N, So A, Chobaz-Péclat V et al. Leptin signaling deficiency impairs humoral and cellular immune re-sponses and attenuates experimental arthritis. J Immunol 2002;168:875-82.
36. Wielinga P, Hooijberg JH, Gunnarsdottir S et al. The human multidrug resistance protein MRP5 transports folates and can mediate cellular resistance against antifolates. Cancer Res 2005;65:4425-30.
37. O'Neill LA, Greene C. Signal transduction pathways activated by the IL-1 receptor family: ancient signaling machinery in mammals, insects, and plants. J Leukoc Biol 1998;63:650-7.
38. Catterall JB, Rowan AD, Sarsfield S, Saklatvala J, Wait R, Cawston TE. Development of a novel 2D proteomics approach for the identification of proteins secreted by primary chondrocytes after stimulation by IL-1 and oncostatin M. Rheumatology 2006;45:1101-9.
39. Chen L, Borozan I, Feld J et al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 2005;128:1437-44.
40. van der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG et al. Responsiveness to anti-tumour necrosis factor alpha therapy is related to pre-treatment tissue inflammation levels in rheumatoid arthritis patients. Ann Rheum Dis 2008;67:563-6.
41. Buch MH, Reece RJ, Quinn MA et al. The value of synovial cytokine expression in predicting the clinical response to TNF antagonist therapy (infliximab). Rheumatology 2008; 47:1469-75.